Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IMM-H014 Sand the Effects of Food on Pharmacokinetics in Healthy Subjects

NCT06216041 is registered in ClinicalTrials.gov with Changchun Intellicrown Pharmaceutical Co. LTD as lead sponsor.

NCT NCT06216041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06216041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IMM-H014 Sand the Effects of Food on Pharmacokinetics in Healthy Subjects
Lead sponsor
Changchun Intellicrown Pharmaceutical Co. LTD
Phase
Phase 1
Overall status
Recruiting
Start date
December 6, 2023
Completion date
August 1, 2025
Enrollment
138 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic steatohepatitis (nash)